Venmax Drugs

Which are the latest news on Venmax Drugs?

Why is Venmax Drugs & Pharmaceuticals Ltd falling/rising?

As of 03-Jun, Venmax Drugs & Pharmaceuticals Ltd's stock price has risen to Rs 22.49, reflecting a 6.19% increase after a trend reversal. Despite this short-term gain and increased investor interest, the stock remains below key moving averages, indicating a bearish long-term outlook.

As of 03-Jun, Venmax Drugs & Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at Rs 22.49, reflecting an increase of Rs 1.31 or 6.19%. This upward movement follows a trend reversal after three consecutive days of decline. Notably, the stock opened with a significant gain of 8.12% today and reached an intraday high of Rs 22.9. <BR><BR>The stock has outperformed its sector by 5.9%, indicating a relatively strong performance compared to its peers. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 430% against the five-day average, suggesting heightened interest in the stock. <BR><BR>Despite the positive movements today, it is important to note that Venmax Drugs is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically indicates a bearish trend in the longer term. The stock has also shown high volatility today, with an intraday volatility of 5.38%. <BR><BR>In summary, the current rise in Venmax Drugs & Pharmaceuticals Ltd's stock price can be attributed to a combination of a trend reversal, strong opening gains, increased investor participation, and outperformance against the sector, despite the overall bearish indicators in the longer-term moving averages.

Are Venmax Drugs & Pharmaceuticals Ltd latest results good or bad?

Venmax Drugs & Pharmaceuticals Ltd's latest results show impressive revenue growth of 1,093.94% year-over-year, but profitability is a concern with a net profit decline of 85.90% and low operating margins. Additionally, a significant drop in promoter shareholding raises questions about the company's financial health and sustainability.

The latest results for Venmax Drugs & Pharmaceuticals Ltd present a mixed picture. On one hand, the company has achieved remarkable revenue growth, with net sales soaring by 1,093.94% year-over-year, increasing from ₹0.33 crores to ₹3.94 crores in Q4 FY26. This significant top-line expansion is a positive indicator of the company's ability to scale its operations.<BR><BR>However, the profitability aspect raises concerns. The net profit for the quarter was only ₹0.11 crores, which represents a staggering decline of 85.90% compared to the same quarter last year. The operating margin is also very low at just 0.25%, indicating that the company is struggling to convert its revenue into profit effectively. Additionally, a substantial portion of the operating profit (90%) came from other income rather than core pharmaceutical operations, which questions the sustainability of its earnings.<BR><BR>The company's financial health is further complicated by a significant drop in promoter shareholding, which has decreased from 23.13% to 13.80% over the past year, signaling a lack of confidence from insiders. Overall, while the revenue growth is impressive, the declining profitability, reliance on non-operational income, and promoter confidence issues suggest that the results are more concerning than positive.

Should I buy, sell or hold Venmax Drugs & Pharmaceuticals Ltd?

When is the next results date for Venmax Drugs & Pharmaceuticals Ltd?

The next results date for Venmax Drugs & Pharmaceuticals Ltd is 14 May 2026.

The next results date for Venmax Drugs & Pharmaceuticals Ltd is scheduled for 14 May 2026.

How has been the historical performance of Venmax Drugs?

Venmax Drugs has experienced significant fluctuations in financial performance, with net sales increasing to 0.81 Cr in March 2025 from 0.00 Cr in the previous year, but overall profitability declined, resulting in a negative profit after tax of -0.01 Cr. Despite growth in sales and total assets, the company faces challenges in maintaining profitability due to rising expenditures and liabilities.

Answer:<BR>The historical performance of Venmax Drugs shows significant fluctuations in its financial metrics over the years, particularly in net sales, operating profit, and overall profitability.<BR><BR>Breakdown:<BR>Venmax Drugs reported net sales of 0.81 Cr in March 2025, a notable increase from 0.00 Cr in March 2024, but still below the 2.55 Cr recorded in March 2015. The total operating income followed a similar trend, reaching 0.81 Cr in March 2025, compared to 0.00 Cr in the previous year. However, total expenditure surged to 1.86 Cr in March 2025, up from 0.10 Cr in March 2024, leading to an operating profit (PBDIT) of 0.00 Cr in March 2025, a decline from 0.10 Cr in March 2024. The profit before tax was slightly negative at -0.01 Cr in March 2025, contrasting with a profit of 0.09 Cr in March 2024. Consequently, the profit after tax also fell to -0.01 Cr in March 2025 from 0.06 Cr in March 2024. The company's total assets increased to 5.17 Cr in March 2025 from 0.08 Cr in March 2024, while total liabilities also rose to 5.17 Cr in March 2025, reflecting a significant increase in short-term borrowings. The cash flow from operating activities was negative at -2.00 Cr in March 2025, although the net cash inflow was positive at 2.00 Cr due to financing activities. Overall, the financial performance of Venmax Drugs indicates challenges in maintaining profitability despite some growth in sales and assets.

How big is Venmax Drugs?

As of 24th July, Venmax Drugs & Pharmaceuticals Ltd has a market capitalization of 16.00 Cr, classifying it as a Micro Cap company, with recent net sales of 1.91 Cr and a net profit of 0.02 Cr over the latest four quarters. Data for shareholder's funds and total assets is unavailable.

As of 24th July, <BR><BR>Market Cap: Venmax Drugs & Pharmaceuticals Ltd has a market capitalization of 16.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1.91 Cr, while the sum of Net Profit for the same period is 0.02 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is the latest annual period, but data for Shareholder's Funds and Total Assets is unavailable.

Who are the top shareholders of the Venmax Drugs?

The top shareholders of Venmax Drugs are Venkat Narender Nuka with 17.69%, and Percy Homi Italia with 8.9%. Individual investors own 65.24% of the company, with no institutional holdings or pledged promoter shares.

The top shareholders of Venmax Drugs include Venkat Narender Nuka, who holds the highest promoter stake at 17.69%. The highest public shareholder is Percy Homi Italia, with a holding of 8.9%. Additionally, individual investors collectively own 65.24% of the company. Notably, there are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

Who are in the management team of Venmax Drugs?

As of March 2018, the management team of Venmax Drugs includes Rajkumar Rai (Managing Director), N Krishnaiah (Non Executive Director), A Ramakrishnaiah (Non Executive Independent Director), N V Narender (Chairman), and Gali Satya Venkata Divya Jyothi (Non Executive Independent Director). Each member contributes to the company's strategic direction.

As of March 2018, the management team of Venmax Drugs includes the following individuals:<BR><BR>1. Rajkumar Rai - Managing Director<BR>2. N Krishnaiah - Non Executive Director<BR>3. A Ramakrishnaiah - Non Executive Independent Director<BR>4. N V Narender - Chairman<BR>5. Gali Satya Venkata Divya Jyothi - Non Executive Independent Director<BR><BR>Each member plays a significant role in guiding the company's strategic direction.

Is Venmax Drugs overvalued or undervalued?

As of December 2, 2024, Venmax Drugs is considered a risky investment due to its overvaluation, reflected in a PE ratio of -12.77, an EV to EBITDA of -9.85, a ROCE of -53.54%, and a recent stock decline of 10.22%, contrasting with the Sensex's 3.83% increase.

As of 2 December 2024, the valuation grade for Venmax Drugs has moved from does not qualify to risky. Based on the analysis, the company is considered overvalued. Key ratios include a PE ratio of -12.77, an EV to EBITDA of -9.85, and a ROCE of -53.54%. <BR><BR>In comparison to its peers, Venmax Drugs has a significantly lower PE ratio than Sun Pharma, which stands at 35.25, and a much less favorable EV to EBITDA ratio compared to Cipla's 15.93. The company's negative performance metrics, alongside its recent stock decline of 10.22% over the past month against a 3.83% increase in the Sensex, further reinforce the notion that Venmax Drugs is not a sound investment at its current valuation.

What is the technical trend for Venmax Drugs?

As of April 1, 2025, Venmax Drugs shows a mildly bullish trend, supported by daily moving averages, but mixed signals from weekly and monthly indicators suggest a cautious outlook.

As of 1 April 2025, the technical trend for Venmax Drugs has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating a positive trend. However, the weekly MACD and KST are mildly bearish, suggesting some caution. The monthly MACD remains bullish, but the monthly RSI is bearish, indicating weakness in momentum. Overall, the mixed signals from various time frames suggest a cautious outlook despite the mildly bullish trend.

What does Venmax Drugs do?

Venmax Drugs & Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 0 Cr and a net profit of 1 Cr for March 2025. It was incorporated in 1998 and has a market cap of Rs 13 Cr.

Overview:<BR>Venmax Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was initially incorporated in 1998 under the name "Yenkay Medico Private Limited" and underwent several name changes, becoming a Public Limited Company in 1995. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 13 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.55 <BR>Return on Equity: -0.23% <BR>Price to Book: 2.85<BR><BR>Contact Details:<BR>Address: H.No 1-140 Rajeswari Warehouse, Kompally Quthbullapur Hyderabad Telangana : 500014 <BR>Email: venmaxdrugs@gmail.com <BR>Website: http://www.venmaxdrugs.com

Has Venmax Drugs declared dividend?

No Dividend History Available

Who are the peers of the Venmax Drugs?

Venmax Drugs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Sun Pharma, Cipla, and Dr Reddy's Labs show excellent management and growth, while Divi's Lab and others have below-average performance in these areas.

Peers: The peers of Venmax Drugs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Decipher Labs, Span Divergent, Unjha Formul., Checkpoint Trend, and Vivanza Biosci.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Average management risk is noted at Decipher Labs and Unjha Formul., while Below Average management risk is present at Checkpoint Trend and Vivanza Biosci. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Decipher Labs, Unjha Formul., and the rest. Capital Structure is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, Good for Torrent Pharma, and Below Average for Decipher Labs, Span Divergent, Checkpoint Trend, and Vivanza Biosci.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Decipher Labs has the lowest at -37.22%, with Venmax Drugs' 1-year return being N/A. Additionally, the six-month returns for Decipher Labs, Span Divergent, Unjha Formul., and Vivanza Biosci. are negative.